Taysha Gene Therapies Q2 2026 Earnings Report

Taysha Gene Therapies EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.11
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Taysha Gene Therapies Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.68 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Taysha Gene Therapies Announcement Details

• Quarter: Q2 2026
• Date: 8/11/2026
• Time: Before Market Opens
• Conference Call Date: Tuesday, August 11, 2026
• Conference Call Time: 4:30PM ET

Taysha Gene Therapies (NASDAQ:TSHA) (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021. The company has secured orphan drug designations from the U.S. Food and Drug Administration for its lead programs and established partnerships to support manufacturing and supply chain needs. With an integrated model that combines in-house research, process development and clinical operations, Taysha aims to accelerate the transition of its candidates from preclinical studies into human trials.

Through collaborations with academic institutions, patient advocacy groups and regulatory agencies, Taysha serves both domestic and international patient populations facing devastating genetic disorders. Its clinical trials are conducted across multiple trial sites in North America and Europe, with a focus on leveraging real-world insights to optimize study design and endpoint selection.

Led by a management team with deep expertise in gene therapy, translational research and rare disease development, Taysha Gene Therapies is committed to building a broad platform capable of delivering potentially transformative treatments for central nervous system disorders. The company continues to expand its scientific and clinical capabilities to bring durable, one-time gene therapies to patients worldwide.